Status:
UNKNOWN
The Changes in Carotid Plaque Neovascularization After Elovocumab Therapy
Lead Sponsor:
Zibo Central Hospital
Conditions:
Carotid Artery Diseases
Eligibility:
All Genders
18-85 years
Brief Summary
150 selected patients will be recruited, who have at least one atherosclerotic plaque in the carotid artery that is thicker than 2.0 mm and which is determined to be uniformly or predominantly echoluc...
Eligibility Criteria
Inclusion
- 1\. have at least one atherosclerotic plaque in the carotid artery that is thicker than 2.0 mm and which is determined to be uniformly or predominantly echolucent by standard ultrasonography;
- patients were referred for optimal medical treatment;
- patients agreed to undergo follow-up CEUS at half-year and 1-year interval.
Exclusion
- patients had previous history of cerebral thrombosis or cerebral embolism;
- patients were contraindicated to the usage of contrast media;
- image quality of baseline or follow-up CEUS was severely impaired (in presence of severe artifact, non-diagnostic);
- patients withdrew the informed consents during follow-up;
- patients experienced major adverse cerebrovascular events during follow-up;
- patients refused to undergo follow-up CEUS;
- lost follow-up
Key Trial Info
Start Date :
August 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 27 2022
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04423406
Start Date
August 1 2020
End Date
February 27 2022
Last Update
April 21 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zibo Central Hospital
Zibo, Shandong, China, 255036